Navigation Links
12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis
Date:8/19/2008

SYDNEY, Australia, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events attributed to the drug following 12 months of treatment.

A total of 123 subjects started treatment with 320 mg Bronchitol twice per day and 99 subjects completed the full 12 months of the trial. Of the 24 withdrawals, only seven were a result of adverse events (three related to lung infections and two related to cough).

The most common adverse events attributed to treatment were cough in 9% of the subjects and sore throat in 5%. Other reported adverse events related to treatment were infrequent, mild in severity and in most cases were a consequence of the underlying disease.

Pharmaxis CEO Alan Robertson said: "Pharmaxis intends to file a marketing application in Australia for Bronchitol as soon as possible now that this study has concluded satisfactorily.

"Bronchitol has created a great deal of interest among people suffering with bronchiectasis and we continue to respond to requests from trial participants and others interested in Bronchitol. We are looking forward to bringing Bronchitol to the market place and are delighted this trial has concluded successfully."

This 12 month treatment period was an open label extension to a three month efficacy trial which reported in the second half of 2007.

The conclusion from this trial is that Bronchitol improves quality of life and mucus clearance following three months of treatment and is safe and well tolerated following 12 months of treatment. The open label component of the trial reported today supports the efficacy reported earlier in the blinded phase of the trial.

Bronchitol is being initially developed as a twice daily inhalation therapy for people with the incurable lung condi
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
6. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
7. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
8. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
9. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
10. Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Attorney Advertising -- Bronstein, Gewirtz ... behalf of purchasers of the securities of Vitae ... VTAE -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether Vitae Pharmaceuticals and certain of its officers ...
(Date:3/2/2015)... 2015  CANTEL MEDICAL CORP. (NYSE: CMN ... CEO, will be presenting at the Sidoti & Company ... presentation is scheduled for 2:00 PM ET on Monday, ... New York . In addition, Mr. Krakauer, ... be available for separate one-on-one meetings during the day. ...
(Date:3/2/2015)... 2, 2015  CytomX, a biotechnology company developing ... announced the creation of scientific and clinical advisory ... the fields of cancer immunotherapy and antibody drug ... will provide guidance to CytomX on the development ... and Probody drug conjugates. The company identified advisors ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
(Date:3/2/2015)... 02, 2015 The minimally invasive ... a CAGR of 6.1% to reach $14,133.0 million ... , Factors such as advantages of minimally invasive ... owing to minimally invasive surgeries and increasing number ... driving the global minimally invasive surgical instruments market. ...
(Date:3/2/2015)... Wailea, Maui Hawaii (PRWEB) March 02, 2015 ... Five-Star resort, is celebrating its 25th anniversary this year, having ... commemorate the milestone, the luxury resort is honoring over 70 ... at the resort -- from amongst the approximately 400 original ... dinner on the Resort’s Oceanfront Lawn. , This ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 The Alliance ... fire safety expert Mark Chubb to serve as chief ... safety operations and training in Bangladesh and guide remediation ... , “Mark will ensure that the Alliance continues ... safety programs for Bangladesh garment workers,” said Alliance Independent ...
(Date:3/2/2015)... Minneapolis, Minnesota (PRWEB) March 02, 2015 ... a new strategic relationship with First Protective Insurance ... new initiative will allow First Protective affiliated advisors ... and implementation support that Secura Consultants delivers. ... is a national leader in the design and ...
(Date:3/1/2015)... Metamora, Michigan (PRWEB) March 01, 2015 ... approved to treat Overactive Bladder (OAB) symptoms, such as a ... adults when another type of medication (anticholinergic) does not work ... different treatment option that takes another approach to targeting the ... BOTOX® works on the nerves and bladder muscle, blocking the ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... BruxZir Solid Zirconia, ... bridge with no porcelain overlay. This new restoration proves strong, reliable and esthetic because of ... ... innovation from Glidewell Dental Lab , is a full-contour solid zirconia crown or bridge ...
... ... thought his story was worth telling. After being diagnosed with Parkinson,s disease ... a manuscript about the experience. Not only could he not find a ... even reading sample chapters. Believing the story needed to be told, Bill ...
... , ... an Atlanta based antivirus company specializing in threat prevention and cloud based antivirus solutions, ... powered mobile devices operate cross carrier and worldwide with Google reporting 60,000 Android handsets ... ...
... ... 32nd Annual National Martial Arts Festival at the Cherry Hill Crowne Plaza Hotel in Cherry Hill, ... (PRWEB) July 1, 2010 -- ... movies, head to Cherry Hill, N.J. The U.S. Soo Bahk Do Moo Duk Kwan Federation, ...
... is already one of medicine,s most successful transplant procedures, ... Now, for the first time, a team of German ... of transplanted corneas are more likely in patients whose ... to surgery. The meta-analysis report appears in July ...
... PA, July 1, 2010 About 1 in 200 women ... 75% of these low-risk, single-baby births planned in advance as ... American Journal of Obstetrics & Gynecology ( AJOG ... results of multiple studies from around the world. They report ...
Cached Medicine News:Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 2Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 3Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 4Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 2Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 3Health News:Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities 4Health News:Bluepoint Security Launches World's First Cloud Antivirus For The Google Android Mobile Platform 2Health News:700 Karate Kids to Converge on Cherry Hill, NJ July 8-10, 2010 2Health News:Study finds new key to corneal transplant success 2Health News:Planned home births associated with tripling of neonatal mortality rate vs. planned hospital births 2
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
Medicine Products: